Trial reportAmerican journal of respiratory and critical care medicine2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.
Open access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine-An Approach for Clinical Management.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Article
- All-Oral Shorter Treatment Regimens for Multidrug- and Rifampicin-Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao PDR.Tropical medicine & international health : TM & IH · 2025Article
- Anti-TB Drugs for Drug-Sensitive and Drug-ResistantCurrent issues in molecular biology · 2025Review
- Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment.Emerging infectious diseases · 2025Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathogens & immunity · 2025Review
- Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.European journal of drug metabolism and pharmacokinetics · 2024Review
- Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2024Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 10 institutions in 3 countries.
Kamunkhwala GausiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-9002-8087
Elisa H IgnatiusDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Veronique De JagerTASK, Cape Town, South Africa.
Caryn UptonTASK, Cape Town, South Africa.
Soyeon KimFrontier Science Foundation, Brookline, Massachusetts.
Ashley McKhannHarvard T. H. Chan School of Public Health, Boston, Massachusetts.
Laura MoranSocial & Scientific Systems, a DLH Company, Silver Spring, Maryland.
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Florian von Groote-BidlingmaierTASK, Cape Town, South Africa.
Philip MarzinekFrontier Science Foundation, Amherst, New York.
Naadira VankerSocial & Scientific Systems, a DLH Company, Silver Spring, Maryland.
Joseph YvetotDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska; and.
Samuel PierreGHESKIO Centers, Port-au-Prince, Haiti.
Susan L RosenkranzFrontier Science Foundation, Brookline, Massachusetts.
Susan SwindellsDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska; and.
Andreas H DiaconSocial & Scientific Systems, a DLH Company, Silver Spring, Maryland.ORCID 0000-0001-8641-6792
Eric L NuermbergerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Paolo DentiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-7494-079X
Kelly E DooleyDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-9013-5256
Task Applied Science · ZAUniversity of Cape Town · ZAFrontier Science & Technology Research Foundation · USGheskio Centers · HTHarvard University · USJohns Hopkins University · USNebraska Medical Center · USSocial and Scientific Systems (United States) · USStellenbosch University · ZAVanderbilt University Medical Center · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MLOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MInternational Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7MUCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4MGHESKIO HIV Clinical Trial UnitUM1AI069421 · NIAID · GHESKIO CENTER · PI JEAN WILLIAM PAPE · 2012 to 2026
$23.6MClinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4MMentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789kEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentInfant Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)National Institute of Allergy and Infectious DiseasesNIAID NIH HHS K24 AI150349NIAID NIH HHS U01 AI068632NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069421NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI106701NIGMS NIH HHS T32 GM066691NIH HHS UM1 AI068634NIMH NIH HHS AI068632
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antitubercular AgentsBacterial ProteinsIsoniazidMutationMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAdultAgedCatalaseDose-Response Relationship, DrugFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedAntitubercular AgentsBacterial ProteinsCatalaseIsoniazidkatG protein, Mycobacterium tuberculosisearly bactericidal activityisoniazid resistancekatG mutationphase 2 clinical trialtuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.